(Reuters) – Atea Pharmaceuticals said on Tuesday a mid-stage trial testing its experimental COVID-19 treatment failed to meet the main goal of reducing the amount of SARS-CoV-2 virus in patients with mild or moderate disease.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shailesh Kuber)
